Profile data is unavailable for this security.
About the company
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.
- Revenue in USD (TTM)0.00
- Net income in USD-29.82m
- Incorporated1995
- Employees22.00
- LocationAchieve Life Sciences Inc22722 29TH DR. SE, SUITE 100SEATTLE 98021United StatesUSA
- Phone+1 (425) 686-1500
- Fax+1 (302) 636-5454
- Websitehttp://achievelifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scilex Holding Co | 46.74m | -166.98m | 142.19m | 105.00 | -- | -- | -- | 3.04 | -1.25 | -1.25 | 0.3587 | -1.73 | 0.4977 | 5.61 | 1.67 | 445,171.40 | -121.73 | -- | -- | -- | 66.45 | -- | -244.59 | -- | 0.17 | -11.86 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| I-Mab ADR | 3.82m | -202.44m | 142.44m | 220.00 | -- | 0.6002 | -- | 37.31 | -2.43 | -2.43 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,355.36 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Syros Pharmaceuticals Inc | 9.94m | -164.57m | 145.40m | 68.00 | -- | 8.64 | -- | 14.64 | -5.77 | -5.77 | 0.3508 | 0.63 | 0.0482 | -- | 11.73 | 146,102.90 | -79.76 | -54.44 | -95.35 | -64.32 | -- | -- | -1,656.51 | -772.82 | -- | -- | 0.7122 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Biostem Technologies Inc | 16.69m | -7.86m | 149.82m | 67.00 | -- | -- | -- | 8.98 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
| ASP Isotopes Inc | 433.03k | -16.29m | 154.60m | 76.00 | -- | 9.49 | -- | 357.01 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -29.82m | 154.82m | 22.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | -0.0684 | 0.00 | -- | -- | 0.00 | -120.85 | -86.31 | -860.46 | -119.59 | -- | -- | -- | -- | -- | -10.66 | 1.10 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Tevogen Bio Holdings Inc | 0.00 | -62.57m | 159.68m | -- | -- | -- | -- | -- | -0.4043 | -0.4043 | 0.00 | -0.5867 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.74 | 42.99 | -- | -- | -- | -41.32 | -- | -- | -- |
| Gossamer Bio Inc | 0.00 | -179.82m | 160.05m | 135.00 | -- | 2.54 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
| Bioatla Inc | 0.00 | -123.46m | 162.12m | 65.00 | -- | 2.29 | -- | -- | -2.58 | -2.58 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -71.49 | -48.72 | -84.01 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| ProQR Therapeutics NV | 10.20m | -30.11m | 162.71m | 157.00 | -- | 3.80 | -- | 15.95 | -0.3718 | -0.3718 | 0.1259 | 0.5261 | 0.0616 | -- | 0.332 | 64,970.48 | -17.94 | -35.51 | -21.82 | -40.51 | -- | -- | -291.18 | -926.31 | -- | -- | 0.3229 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Seres Therapeutics Inc | 126.33m | -113.72m | 163.09m | 233.00 | -- | -- | -- | 1.29 | -0.897 | -0.897 | 0.9829 | -0.3322 | 0.3572 | -- | -- | 542,167.40 | -32.15 | -41.51 | -43.48 | -54.13 | -- | -- | -90.02 | -170.14 | 1.48 | -18.38 | 1.79 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Scpharmaceuticals Inc | 13.59m | -54.81m | 163.69m | 135.00 | -- | 4.39 | -- | 12.04 | -1.42 | -1.42 | 0.353 | 1.03 | 0.1243 | 0.7569 | -- | 100,688.90 | -50.13 | -38.23 | -55.33 | -42.31 | 71.96 | -- | -403.22 | -1,360.16 | 6.40 | -18.35 | 0.5105 | -- | -- | -- | -48.79 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -30.04m | 164.32m | 30.00 | -- | 2.40 | -- | -- | -1.59 | -1.59 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -77.55 | -53.74 | -104.84 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.0592 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Capricor Therapeutics Inc | 25.18m | -22.29m | 167.91m | 101.00 | -- | 7.35 | -- | 6.67 | -0.8708 | -0.8708 | 0.9403 | 0.7256 | 0.4627 | -- | 4.61 | 249,287.80 | -40.96 | -54.12 | -82.59 | -75.13 | -- | -- | -88.52 | -316.25 | -- | -- | 0.13 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Alpha Tau Medical Ltd | 0.00 | -29.16m | 169.30m | 121.00 | -- | 2.00 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Achieve Life Sciences Inc's reporting currency: US Dollar USD
14.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Franklin Advisers, Inc.as of 29 Feb 2024 | 2.18m | 6.38% |
| Shay Capital LLCas of 31 Dec 2023 | 725.00k | 2.12% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 597.57k | 1.75% |
| Francis Capital Management LLCas of 31 Dec 2022 | 432.43k | 1.26% |
| Long Focus Capital Management LLCas of 31 Dec 2023 | 248.10k | 0.72% |
| Geode Capital Management LLCas of 31 Dec 2023 | 184.93k | 0.54% |
| LPL Financial LLCas of 31 Dec 2023 | 178.50k | 0.52% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 151.85k | 0.44% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 90.16k | 0.26% |
| Walleye Capital LLCas of 31 Dec 2023 | 82.60k | 0.24% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
